Sort by
Items per page

Send to

Choose Destination

Best matches for diabetes; fatty acid oxidation; glucose oxidation; heart failure:

Search results

Items: 1 to 20 of 97


Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date.

Athithan L, Gulsin GS, McCann GP, Levelt E.

World J Diabetes. 2019 Oct 15;10(10):490-510. doi: 10.4239/wjd.v10.i10.490. Review.


Disturbed Fatty Acid Oxidation, Endoplasmic Reticulum Stress, and Apoptosis in Left Ventricle of Patients With Type 2 Diabetes.

Ljubkovic M, Gressette M, Bulat C, Cavar M, Bakovic D, Fabijanic D, Grkovic I, Lemaire C, Marinovic J.

Diabetes. 2019 Oct;68(10):1924-1933. doi: 10.2337/db19-0423. Epub 2019 Aug 7.


Metabolic Profiling of the Diabetic Heart: Toward a Richer Picture.

Sowton AP, Griffin JL, Murray AJ.

Front Physiol. 2019 May 31;10:639. doi: 10.3389/fphys.2019.00639. eCollection 2019. Review.


Contribution of Impaired Insulin Signaling to the Pathogenesis of Diabetic Cardiomyopathy.

Zamora M, Villena JA.

Int J Mol Sci. 2019 Jun 11;20(11). pii: E2833. doi: 10.3390/ijms20112833. Review.


The cardioprotective effects of carvedilol on ischemia and reperfusion injury by AMPK signaling pathway.

Hu H, Li X, Ren D, Tan Y, Chen J, Yang L, Chen R, Li J, Zhu P.

Biomed Pharmacother. 2019 Sep;117:109106. doi: 10.1016/j.biopha.2019.109106. Epub 2019 Jun 11.


Trimetazidine in cardiovascular medicine.

Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, Etriby E, Ferrari R, Gowdak LH, Lopatin Y, Milicic D, Parkhomenko A, Pinto F, Ponikowski P, Seferovic P, Rosano GMC.

Int J Cardiol. 2019 Oct 15;293:39-44. doi: 10.1016/j.ijcard.2019.05.063. Epub 2019 May 24.


Weight loss enhances cardiac energy metabolism and function in heart failure associated with obesity.

Karwi QG, Zhang L, Altamimi TR, Wagg CS, Patel V, Uddin GM, Joerg AR, Padwal RS, Johnstone DE, Sharma A, Oudit GY, Lopaschuk GD.

Diabetes Obes Metab. 2019 Aug;21(8):1944-1955. doi: 10.1111/dom.13762. Epub 2019 Jun 4.


Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.

Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.

Eur J Heart Fail. 2019 Jul;21(7):862-873. doi: 10.1002/ejhf.1473. Epub 2019 Apr 29.


The effect of apelin-13 on pancreatic islet beta cell mass and myocardial fatty acid and glucose metabolism of experimental type 2 diabetic rats.

Feng J, Zhao H, Du M, Wu X.

Peptides. 2019 Apr;114:1-7. doi: 10.1016/j.peptides.2019.03.006. Epub 2019 Apr 4.


Metabolic remodelling of glucose, fatty acid and redox pathways in the heart of type 2 diabetic mice.

Cortassa S, Caceres V, Tocchetti CG, Bernier M, de Cabo R, Paolocci N, Sollott SJ, Aon MA.

J Physiol. 2018 Nov 21. doi: 10.1113/JP276824. [Epub ahead of print]


Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.

Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD.

JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587. doi: 10.1016/j.jacbts.2018.07.006. eCollection 2018 Oct.


Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts.

Birkenfeld AL, Jordan J, Dworak M, Merkel T, Burnstock G.

Pharmacol Ther. 2019 Feb;194:132-144. doi: 10.1016/j.pharmthera.2018.08.015. Epub 2018 Aug 25. Review.


Propionate-induced changes in cardiac metabolism, notably CoA trapping, are not altered by l-carnitine.

Wang Y, Christopher BA, Wilson KA, Muoio D, McGarrah RW, Brunengraber H, Zhang GF.

Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E622-E633. doi: 10.1152/ajpendo.00081.2018. Epub 2018 Jul 17.


Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.

Jung HY, Kim B, Ryu HG, Ji Y, Park S, Choi SH, Lee D, Lee IK, Kim M, Lee YJ, Song W, Lee YH, Choi HJ, Hyun CK, Holzapfel WH, Kim KT.

Diabetes Obes Metab. 2018 Jul;20(7):1688-1701. doi: 10.1111/dom.13284. Epub 2018 Apr 14.


Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction.

Ussher JR, Campbell JE, Mulvihill EE, Baggio LL, Bates HE, McLean BA, Gopal K, Capozzi M, Yusta B, Cao X, Ali S, Kim M, Kabir MG, Seino Y, Suzuki J, Drucker DJ.

Cell Metab. 2018 Feb 6;27(2):450-460.e6. doi: 10.1016/j.cmet.2017.11.003. Epub 2017 Dec 21.


Peroxisome proliferator-activated receptors as therapeutic targets for heart failure.

Abushouk AI, El-Husseny MWA, Bahbah EI, Elmaraezy A, Ali AA, Ashraf A, Abdel-Daim MM.

Biomed Pharmacother. 2017 Nov;95:692-700. doi: 10.1016/j.biopha.2017.08.083. Epub 2017 Sep 7. Review.


The 'Goldilocks zone' of fatty acid metabolism; to ensure that the relationship with cardiac function is just right.

Kerr M, Dodd MS, Heather LC.

Clin Sci (Lond). 2017 Jul 24;131(16):2079-2094. doi: 10.1042/CS20160671. Print 2017 Aug 15. Review.


Integration of flux measurements to resolve changes in anabolic and catabolic metabolism in cardiac myocytes.

Gibb AA, Lorkiewicz PK, Zheng YT, Zhang X, Bhatnagar A, Jones SP, Hill BG.

Biochem J. 2017 Aug 7;474(16):2785-2801. doi: 10.1042/BCJ20170474. Erratum in: Biochem J. 2017 Dec 14;474(24):4271-4272.


Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure.

Breedt E, Lacerda L, Essop MF.

PLoS One. 2017 Jun 20;12(6):e0179509. doi: 10.1371/journal.pone.0179509. eCollection 2017.


Complex Energy Metabolic Changes in Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction.

De Jong KA, Lopaschuk GD.

Can J Cardiol. 2017 Jul;33(7):860-871. doi: 10.1016/j.cjca.2017.03.009. Epub 2017 Mar 19. Review.


Supplemental Content

Loading ...
Support Center